Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...

SAN DIEGO, CA, USA I June 05, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

BOSTON, MY, USA I June 5, 2025 I Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has ...

SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases ...

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO, IL, USA I June 05, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

BEIJING, China & NANJING, China, China I June 04, 2025 I Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai ...

I On May 30, 2025, Conjustar Biologics announced that it's EphA2 targeting PDC drug SC-102 has received Investigational New Drug (IND) approval ...